Literature DB >> 19614802

Intensive monitoring of adherence to treatment helps to identify "true" resistant hypertension.

Walnéia Aparecida de Souza1, Maricene Sabha, Fabrício de Faveri Favero, Gun Bergsten-Mendes, Juan Carlos Yugar-Toledo, Heitor Moreno.   

Abstract

Intensive monitoring of adherence in patients with uncontrolled hypertension was evaluated over a 6-month period. After that period, only patients well characterized as having resistant hypertension were followed for 12 months. The goal of this study was to evaluate whether adherence to a drug regimen helps to identify patients with resistant hypertension. Forty-four hypertensive patients resistant to a 3-drug regimen (average blood pressure [BP] mm Hg, mean +/- standard deviation) were studied prospectively. Each patient was followed for a 12-month period. Adherence to treatment was evaluated through self-report, applying Morisky's questionnaire and the pill count method. Ambulatory BP monitoring and office BP measures were performed. By pill count, 63.6% of the patients were adherent to treatment at the start of the survey and 94% at the end, although 59% of the patients still did not reach normal BP levels. We found that non-adherence was not associated with resistance to antihypertensive treatment. Therefore, after investigation, we concluded that patients who presented with uncontrolled arterial BP may be truly resistant hypertensive to treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19614802      PMCID: PMC8673126          DOI: 10.1111/j.1751-7176.2009.00102.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  23 in total

Review 1.  Clinical practice. Resistant or difficult-to-control hypertension.

Authors:  Marvin Moser; John F Setaro
Journal:  N Engl J Med       Date:  2006-07-27       Impact factor: 91.245

2.  Pharmacoadherence: a new term for a significant problem.

Authors:  Marie A Chisholm-Burns; Christina A Spivey
Journal:  Am J Health Syst Pharm       Date:  2008-04-01       Impact factor: 2.637

3.  True resistant hypertension: is it possible to be recognized in the office?

Authors:  Elizabeth Silaid Muxfeldt; Katia Vergetti Bloch; Armando da Rocha Nogueira; Gil Fernando Salles
Journal:  Am J Hypertens       Date:  2005-12       Impact factor: 2.689

Review 4.  Compliance with medical regimens during adolescence.

Authors:  I F Litt; W R Cuskey
Journal:  Pediatr Clin North Am       Date:  1980-02       Impact factor: 3.278

5.  Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions.

Authors:  M Burnier; M P Schneider; A Chioléro; C L Stubi; H R Brunner
Journal:  J Hypertens       Date:  2001-02       Impact factor: 4.844

6.  Effect of pharmaceutical care on blood pressure control and health-related quality of life in patients with resistant hypertension.

Authors:  Walnéia Aparecida de Souza; Juan Carlos Yugar-Toledo; Gun Bergsten-Mendes; Maricene Sabha; Heitor Moreno
Journal:  Am J Health Syst Pharm       Date:  2007-09-15       Impact factor: 2.637

Review 7.  Resistant hypertension: an overview.

Authors:  F A McAlister; R Z Lewanczuk; K K Teo
Journal:  Can J Cardiol       Date:  1996-09       Impact factor: 5.223

8.  Concurrent and predictive validity of a self-reported measure of medication adherence.

Authors:  D E Morisky; L W Green; D M Levine
Journal:  Med Care       Date:  1986-01       Impact factor: 2.983

9.  Prevalence and trends in obesity among US adults, 1999-2000.

Authors:  Katherine M Flegal; Margaret D Carroll; Cynthia L Ogden; Clifford L Johnson
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

Review 10.  State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension.

Authors:  Pantelis A Sarafidis; George L Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-02       Impact factor: 3.738

View more
  13 in total

1.  Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension.

Authors:  Marguerite R Irvin; Daichi Shimbo; Devin M Mann; Kristi Reynolds; Marie Krousel-Wood; Nita A Limdi; Daniel T Lackland; David A Calhoun; Suzanne Oparil; Paul Muntner
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-08-03       Impact factor: 3.738

2.  The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension.

Authors:  Stacie L Daugherty; J David Powers; David J Magid; Frederick A Masoudi; Karen L Margolis; Patrick J O'Connor; Julie A Schmittdiel; P Michael Ho
Journal:  Hypertension       Date:  2012-06-25       Impact factor: 10.190

Review 3.  Can drugs work in patients who do not take them? The problem of non-adherence in resistant hypertension.

Authors:  Marcel Ruzicka; Swapnil Hiremath
Journal:  Curr Hypertens Rep       Date:  2015-09       Impact factor: 5.369

4.  Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement.

Authors:  Hemal Bhatt; Mohammed Siddiqui; Eric Judd; Suzanne Oparil; David Calhoun
Journal:  J Am Soc Hypertens       Date:  2016-03-30

Review 5.  Medication adherence and resistant hypertension.

Authors:  D J Hyman; V Pavlik
Journal:  J Hum Hypertens       Date:  2014-09-11       Impact factor: 3.012

Review 6.  A systematic review of patient self-reported barriers of adherence to antihypertensive medications using the world health organization multidimensional adherence model.

Authors:  Suliman A AlGhurair; Christine A Hughes; Scot H Simpson; Lisa M Guirguis
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-08-20       Impact factor: 3.738

7.  Common secondary causes of resistant hypertension and rational for treatment.

Authors:  Charles Faselis; Michael Doumas; Vasilios Papademetriou
Journal:  Int J Hypertens       Date:  2011-03-02       Impact factor: 2.420

8.  Relationship of autonomic imbalance and circadian disruption with obesity and type 2 diabetes in resistant hypertensive patients.

Authors:  Leandro Boer-Martins; Valéria N Figueiredo; Caroline Demacq; Luiz C Martins; Fernanda Consolin-Colombo; Márcio J Figueiredo; Fernando P S Cannavan; Heitor Moreno
Journal:  Cardiovasc Diabetol       Date:  2011-03-22       Impact factor: 9.951

Review 9.  Effects of PDE type 5 inhibitors on left ventricular diastolic dysfunction in resistant hypertension.

Authors:  Ana Paula Cabral de Faria; Rodrigo Modolo; Beatriz Vaz Domingues Moreno; Heitor Moreno
Journal:  Arq Bras Cardiol       Date:  2014-10-28       Impact factor: 2.000

10.  A Proposed Inflammatory Score of Circulating Cytokines/Adipokines Associated with Resistant Hypertension, but Dependent on Obesity Parameters.

Authors:  Ana Paula de Faria; Alessandra Mileni Versuti Ritter; Carolina Souza Gasparetti; Nathália Batista Corrêa; Veridiana Brunelli; Aurélio Almeida; Nayara Fraccari Pires; Rodrigo Modolo; Heitor Moreno Junior
Journal:  Arq Bras Cardiol       Date:  2019-02-28       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.